Final answer:
The frequency of reports a pharmacist must provide in collaborative drug therapy management varies and is not specified in the question; however, adverse events are reported to the FDA on specific time frames post-approval of a drug.
Step-by-step explanation:
The frequency at which a pharmacist engaged in collaborative drug therapy management must furnish a report to the provider can vary based on specific regulations and agreements. However, the question as presented does not specify a particular set of guidelines or jurisdiction to provide a definitive answer. It's important to note that in the context of adverse drug experiences after a drug has been approved, the sponsor must report serious and fatal adverse events to the FDA within 15 days, and other types of events on a quarterly basis.
Additionally, pharmacists might be subject to institutional or local rules that determine the frequency of reporting in collaborative care settings. In cases like directly observed therapy (DOT) for TB, the structure might inherently include regular progress reports due to the close monitoring required.